Base de dados : CRT-Acervo
Pesquisa : CONTAGEM DE LINFOCITO CD4 [Descritor de assunto]
Referências encontradas : 8 [refinar]
Mostrando: 1 .. 8   no formato [Detalhado]

página 1 de 1

  1 / 8 CRT-Acervo  
              next record last record
seleciona
para imprimir
Texto Completo
Id:7286
Autor:Ewi, David S; Suleiman, Jamal M; Uip, David E; Pedro, Rogerio J; Souza, Rosa A; Suleiman, Grace S; Accetturi, Conceição; Leite, Olavo M; Abreu, William B; Kalichman, Artur O; Moraes Filho, Joaquim P. P; Motti, Eduardo F; Pecoraro, Maria Lucia C; Makurath, Mark R; Nessly, Michael L; Leavitt, Randi Y.
Título:Randomized, double-blind trial comparing indinavir alone, zidovudine alone and indinavir plus zidovudine in antiretroviral therapy-naive hiv-infected individuals with CD4 cell counts between 50 and 250/mm3.
Fonte:Rev. Inst. Med. Trop. São Paulo;42(1):27-36, Jan.-Feb. 2000. tab, gra.
Resumo:Treatment with indinavir has been shown to result in marked decreases in viral load and increases in CD4 cell counts in HIV-infected individuals. A randomized double-blind study to evaluate the efficacy of indinavir alone (800 mg q8h), zidovidine alone (200 mg q8h) or the combination was performed to evaluate progression to AIDS. 996 antiretroviral therapy-naive patients with CD4 cell counts of 50-250/mm3 were allocated to treatment. During the trial the protocol was amended to add lamivudine to the zidovudine-containing arms. The primary endpoint was time to development of an AIDS-defining illness or death. The study was terminated after a protocol-defined interim analysis demonstrated highly significant reductions in progression to a clinical event in the indinavir-containing arms, compared to the zidovudine arm (<0.0001). Over a median follow-up of 52 weeks (up to 99 weeks), percent reductions in hazards for the indinavir plus zidovudine and indinavir groups compared to the zidovudine group were 70 percent and 61 percent, respectively. Significant reductions in HIV RNA and increases in CD4 cell counts were also seen in the indinavir-containing groups compared to the zidovudine group. Improvement in both CD4 cell count and HIV RNA were associated with reduced risk of disease progression. All three regimens were generally well tolerated (AU).
Descritores:Infecções por HIV/quimioter
Indinavir/uso terap
Inibidores da Protease HIV/uso terap
Zidovudina/uso terap
Agentes Anti-HIV/uso terap
Protocolos Clínicos
Contagem de Linfócito CD4/ef drogas
Método Duplo-Cego
 Seguimentos
 Infecções por HIV/sangue
 Carga Viral
 Progressão da Doença
 RNA Viral/ef drogas
 Intervalos de Confiança
 Quimioterapia Combinada
Limites:Humanos
Feminino
Adulto
Estudo Comparativo
Meio Eletrônico:http://www3.crt.saude.sp.gov.br/arquivos/arquivos_...
Localização:BR1310.1; Formato Eletrônico


  2 / 8 CRT-Acervo  
              first record previous record next record last record
seleciona
para imprimir
Texto Completo
Id:7033
Autor:MINISTÉRIO DA SAÚDE. SECRETARIA DE ATENÇÃO À SAÚDE.
Título:Portaria MS-SAS nº 82, de 24/02/11.
Fonte:Diário Ofícial da Imprensa Nacional;seção 1(42):51-51, Março 01, 2011. ^btab.
Resumo:Habilita os estabelecimentos informados para realizar a quantificação de carga viral do HIV-1 e contagem de linfócitos CD4+/CD8^ipt.
Descritores:Carga Viral
HIV-1
Contagem de Linfócito CD4
Antígenos CD8
Meio Eletrônico:ftp://ftp.saude.sp.gov.br/ftpsessp/bibliote/inform...
Localização:Br1310.1; Formato Eletronico


  3 / 8 CRT-Acervo  
              first record previous record next record last record
seleciona
para imprimir
Texto Completo
Id:6743
Autor:Almeida, Lanamar Aparecida
Título:Aspectos tomográficos da tuberculose pulmonar em pacientes adultos com AIDS ..-
Fonte:São Paulo; s.n; 2009. 68 p. .
Tese:Apresentada a Secretaria de Estado da Saúde. Coordenadoria de Controle de Doenças para obtenção do grau de Mestre.
Descritores:Síndrome de Imunodeficiência Adquirida
Tuberculose Pulmonar
Tomografia Computadorizada Espiral
Tórax
HIV
Contagem de Linfócito CD4
Limites:Humanos
Adulto
Meio Eletrônico:http://www.crt.saude.sp.gov.br/resources/crt_aids/...
Localização:BR1310.1; Formato Eletrônico


  4 / 8 CRT-Acervo  
              first record previous record next record last record
seleciona
para imprimir
Texto Completo
Id:3344
Autor:Viso, Ana T Rodriguez; Oliveira, Augusto C. Penalva de; Boas, Lucy S Vilas.
Título:Cytomegalovirus Glycoprotein B Genotypes and Central Nervous System Disease in AIDS Patients.
Fonte:J Med Virol;71(3):404-407, Nov. 2003. tab.
Resumo:To investigate any association between cytomegalovirus glycoprotein B (CMV gB) subtypes and central nervous system (CNS) disease in AIDS patients, proportions of different gB genotypes detected in AIDS patients with CNS disease were compared with the gB genotypes detected in AIDS patients with no neurological disorder. The patients were matched by CD4+ cell counts. CMV was detected by PCR in cerebrospinal fluid (CSF) samples obtained from AIDS patients with CNS disease and from urine and saliva samples obtained from AIDS patients without CNS disease. CMV strains obtained were digested by restriction enzymes HinffI and RsaI to classify the genotypes. The CMV gB genotype was determined in 26 CSF samples. Of these, 11/26 (42.3 por cento) typed as gB group 1, seven (26.9 por cento) as gB2, four (15.4 por cento) as gB3, and four (15.4 por cento) as gB4. The CMV gB genotype frequency distribution in the 42 AIDS patients without CNS disease showed that 18/42 (42.8 por cento) were classified as gB group 1, 10 (23.8 por cento) as gB2, seven (16.6 por cento) as gB3, and seven (16.6 por cento) as gB4. In the present study, no association was found between CMV gB genotypes and CMV-related central nervous system disease.
Descritores:Infecções Oportunistas Relacionadas com a AIDS/fisiopatol
Infecções Oportunistas Relacionadas com a AIDS/virol
Contagem de Linfócito CD4
Infecções do Sistema Nervoso Central/fisiopatol
Infecções do Sistema Nervoso Central/virol
Citomegalovirus/clas
Citomegalovirus/genet
Citomegalovirus/isol
Citomegalovirus/patogen
DNA Viral/lcr
Genótipo
Infecções por HIV/compl
Infecções por HIV/virol
Reação em Cadeia da Polimerase
Proteína de Invólucro Viral/genet
Limites:Humano
Meio Eletrônico:http://www3.crt.saude.sp.gov.br/arquivos/arquivos_...
Localização:BR1310.1; Formato Eletrônico


  5 / 8 CRT-Acervo  
              first record previous record next record last record
seleciona
para imprimir
Id:3313
Autor:Yoshioka, MC; Alchorne, MM; Porro, AM;; Tomimori-Yamashita, J.
Título:Epidemiology of Kaposi's sarcoma in patients with acquired immunodeficiency syndrome in São Paulo, Brazil.
Fonte:Int J Dermatol;43(9):643-647, sep.2004. tab.
Resumo:BACKGROUND: Kaposi's sarcoma (KS) is the most frequent neoplasm in patients with acquired immunodeficiency syndrome (AIDS). Although many studies on KS epidemiology have been performed in other countries, few have been carried out in Brazil despite the high incidence of AIDS. METHODS: One hundred and seven KS patients seen in São Paulo, Brazil, between August 1995 and November 1998 were studied. The patients were followed for 1 year with assessment of the immunologic status, improvement of the lesions, treatment, and causes of death at the end of this period. RESULTS: KS occurred mainly in men (94.4%) with a mean age of 37 years, and 25.2% of these patients were found to be human immunodeficiency virus (HIV) seropositive through KS. HIV was acquired mainly through homosexual contact. The patients presented an average of 15.9 KS lesions at the first visit and the mean duration of KS lesions before the first visit was 15.5 months. The clinical presentation was predominantly papules and plaques, and 33.6% presented with mucosal and/or visceral disease. KS affected mainly the lower limbs. The mean time since the diagnosis of HIV infection was 42.4 months. The CD4+ cell count was lower than 200 cell/mm(3) in 60.8% of patients, but patients with a complete response showed an improvement in immune status after 1 year. Patients who did not show progression received a protease inhibitor as part of highly active antiretroviral therapy (HAART). Patients treated exclusively with HAART presented a complete response (61.6%), partial response (23%) or progression (15.4%) of KS. CONCLUSIONS: An improvement in immune status and the use of HAART were the most important prognostic features.
Descritores:Terapia Anti-Retroviral de Alta Atividade
Contagem de Linfócito CD4
Sarcoma de Kaposi/compl
Sarcoma de Kaposi/quimioter
Sarcoma de Kaposi/epidemiol
Neoplasias Cutâneas/compl
Neoplasias Cutâneas/quimioter
Neoplasias Cutâneas/epidemiol
Síndrome de Imunodeficiência Adquirida/compl
 Brasil/epidemiol
Limites:Humano
Masculino
Feminino
Adulto
Meia-Idade
Meio Eletrônico:
Localização:BR1310.1; PAPROF


  6 / 8 CRT-Acervo  
              first record previous record next record last record
seleciona
para imprimir
Id:3286
Autor:Brindeiro, Rodrigo M; Teixeira, Paulo R.
Título:Brazilian Network for HIV Drug Resistance Surveillance (HIV-BResNet): a survey of chronically infected individuals.
Fonte:AIDS;17(7):1063-1069, mai.2003. .
Resumo:OBJECTIVE: To study the prevalence of HIV drug resistance mutations and subtype distribution in a Brazilian drug-naive population. Asymptomatic, drug-naive HIV-1-infected individuals were targeted in 13 voluntary counseling and testing centers spread around the country. METHODS: Plasma viral RNA was extracted from 535 HIV-1-positive subjects. Protease (PR) and reverse transcriptase (RT) genomic regions were sequenced for subtype determination and analysis of drug resistance mutations. RESULTS: Eight samples (2.24 %) showed primary mutations related to protease inhibitor (PI) resistance, eight (2.36%) to nucleoside reverse transcriptase inhibitors (NRTI) and seven (2.06%) to non-nucleoside reverse transcriptase inhibitors (NNRTI). Accessory mutations were found in the PR gene at the following positions: L63P/V/T/A/I [153/345 (44.3%)], M36I/L [149/345 (43.2%)], L10I/F/V [82/345 (23.8%)], V77I [60/345 (17.4%)], A71V/T [11/345 (3.2%)], K20M/R [10/345 (2.9%)], and V82I [4/345 (1.2%)]. Mutations known to be associated with reduced sensitivity to NRTI or NNRTI (V118I, E44D, K219R, T69A, and V75L) were found in a low prevalence (0.6-2.4%). A high proportion of the isolates from subtype C was found in the southern states. Subtype F-related viruses were the main non-B variant in the rest of the country. CONCLUSIONS:Brazil has a low prevalence of drug-resistant strains circulating among recently diagnosed individuals. However, there was an increase in these rates compared with similar studies performed with samples collected in Brazil from 1996 to 1998. Continued surveys are required to detect trends in these rates, but routine genotypic testing in the drug-naive population prior to antiretroviral initiation is not required in Brazil.
Descritores:Síndrome de Imunodeficiência Adquirida/quimioter
Síndrome de Imunodeficiência Adquirida/imunol
Síndrome de Imunodeficiência Adquirida/mortal
Agentes Anti-HIV/uso terap
Contagem de Linfócito CD4
Taxa de Sobrevivência
Análise Multivariada
 Acesso Aos Serviços de Saúde
 Brasil/epidemiol
 Países em Desenvolvimento
 Estudos Retrospectivos
Limites:Humano
Masculino
Feminino
Adulto
Localização:BR1310.1; PAPROF


  7 / 8 CRT-Acervo  
              first record previous record next record last record
seleciona
para imprimir
Id:1155
Autor:BEATRIZ JULIAO VIEIRA; DANIELA FIGUEIREDO FONSECA; JOANA ALVIM COTTA.
Título:O PAPEL DOS LINFOCITOS T NA PERIODONTITE DO ADULTO EM PACIENTES HIV POSITIVOS.
Fonte:JORNAL BRASILEIRO DE AIDS;2(2):7, abr.jun.22001. ilus, tab, graf.
Resumo:A INCIDENCIA DA PERIODONTITE EM INDIVIDUOS INFECTADOS PELO HIV E MAIS ALTA QUANDO COMPARADA A INDIVIDUOS HIV.NEST`E ESTUDO INVESTIGAMOS A EXTENSAO DA REACAO INFLAMATORIA E QUANTIFICAMOS O TIPO DE CELULA INFLAMATROIRA NO SITIO DA LESAO PERIODONTAL.
Descritores:LINFOCITOS T
AIDS
SINDROME DE IMUNODEFICIENCIA ADQUIRIDA
CONTAGEM DE LINFOCITO CD4
LINFOCITO T
DOENCA PERIODONTAL
RESPOSTA INFLAMATORIA
IMUNOSSUPRESSAO
HIV
 LINFOCITO
Limites:HUMANO
Localização:BR1310.1


  8 / 8 CRT-Acervo  
              first record previous record
seleciona
para imprimir
Id:216
Autor:MINISTERIO.
Título:CONSENSO BRASILEIRO.
Fonte:CADERNOS PELA VIDDA;ED. ESPECIAL:14, 1997. .
Descritores:AIDS
MINISTERIO
CD4
CARGA VIRAL
RECOMENDACOES
TRATAMENTO
QUADRO
TABELA
ORIENTACAO
COQUETEL
TERAPIA
ESTATISTICA
CONTAGEM DE LINFOCITO CD4
SINTOMAS
POLITICA DE NUTRI€AO
RESULTADO DE TRATAMENTO
HIV
 TRATAMENTO
Limites:HUMANO
ADULTO
Localização:BR1310.1



página 1 de 1
   


Refinar a pesquisa
  Base de dados : Formulário avançado   
Pesquisar por : Formulário livre   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6.3 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information